Lemme
US$ 29.97
glp 1 drugs risks GLP-1 and Eating Disorders: A Hidden Risk in the Weight Loss Revolution – The Chicago Council on Science and Technology Your guide to GLP-1 side
Description
30 Bouchoucha, M., B
A growing body of research shows GLP-1 receptor agonists lower the risk of major cardiovascular events, including heart attacks and strokes, particularly in people with Type 2 diabetes
Activating them improves insulin sensitivity and may enhance fat metabolism through pathways that GLP-1 alone does not reach
[PubMed ID: 29364584]
Weight change in the placebo group was 3.1% (95% CI, 4.3 to 1.9)
